The Science Behind Retatrutide's Triple Mechanism Each of retatrutide's three receptor targets contributes unique metabolic benefits: GIP Receptor Activation: Enhances insulin secretion in response to food intake Influences fat metabolism and storage patterns Modulates bone metabolism and cardiovascular function Complements GLP-1 effects for improved glycemic control GLP-1 Receptor Activation: Stimulates insulin release while suppressing glucagon Slows gastric emptying to extend satiety Reduces appetite through central nervous system pathways Provides cardiovascular protective effects Glucagon Receptor Activation: Increases energy expenditure and metabolic rate Promotes fat oxidation and lipolysis Helps prevent metabolic adaptation during weight loss Balances the anabolic effects of insulin signaling This triple-action approach explains why retatrutide demonstrated remarkable results in phase 2 clinical trials, with participants experiencing up to 24.2% body weight reduction at 48 weeks [4]

These incretin effects explain the initially surprising weight loss observed in the treatment groups of the cardiovascular trials, with subjects taking GLP-1/GIP agonists losing from 3% to 12% of their body weight
With a PDUFA date of April 10, 2026, Orforglipron is projected to hit $1B in sales in its launch year, with a long-term peak sales range of **$25B$43B** (per foreign institutional forecasts)
High-fiber foods such as whole grains, nuts, fruits, and veggies can relieve constipation on Zepbound
By identifying these foods and eliminating them from your diet, you can reduce the frequency and intensity of your migraine